Study GIPF-004 is an open-label, multicenter study that will enroll approximately 250
patients who complete Protocol GIPF-001. The purpose of this study is to assess the safety
and efficacy of continued IFN-gamma 1b therapy in this well-defined cohort of patients for
up to 48 weeks.
Male or Female
Idiopathic Pulmonary Fibrosis
Must have participated in the InterMune protocol GIPF-001 study.